0000000000482264

AUTHOR

Jose I. Mayordomo

showing 2 related works from this author

Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior

2010

Contains fulltext : 89305.pdf (Publisher’s version ) (Closed access) Smoking is a common risk factor for many diseases. We conducted genome-wide association meta-analyses for the number of cigarettes smoked per day (CPD) in smokers (n = 31,266) and smoking initiation (n = 46,481) using samples from the ENGAGE Consortium. In a second stage, we tested selected SNPs with in silico replication in the Tobacco and Genetics (TAG) and Glaxo Smith Kline (Ox-GSK) consortia cohorts (n = 45,691 smokers) and assessed some of those in a third sample of European ancestry (n = 9,040). Variants in three genomic regions associated with CPD (P < 5 x 10(-8)), including previously identified SNPs at 15q25 repre…

MaleNetherlands Twin Register (NTR)Lung NeoplasmsSingle-nucleotide polymorphismGenome-wide association studyAetiology screening and detection [ONCOL 5]Receptors NicotinicGenetic analysisArticleMolecular epidemiology [NCEBP 1]Cohort Studies03 medical and health sciences0302 clinical medicineSDG 3 - Good Health and Well-beingOdds RatioGeneticsmedicine/dk/atira/pure/keywords/cohort_studies/netherlands_twin_register_ntr_HumansCYP2A6Lung cancerAlleles030304 developmental biologyGenetics0303 health sciencesbiologyCHRNA6CHRNA5Hormonal regulation [IGMD 6]SmokingGenetic VariationGenomicsTobacco Use DisorderOdds ratiomedicine.disease3. Good healthPhenotypeEvaluation of complex medical interventions [NCEBP 2]genome-wide association nicotinic acetylcholine-receptors lung-cancer susceptibility locus molecular-genetics heavy smoking adult twins dependence genes snpsbiology.protein/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingFemaleAryl Hydrocarbon Hydroxylases030217 neurology & neurosurgeryGenome-Wide Association Study
researchProduct

Nonpegylated Liposomal Doxorubicin (TLC-D99), Paclitaxel, and Trastuzumab in HER-2-Overexpressing Breast Cancer: A Multicenter Phase I/II Study

2008

Abstract Purpose: To determine the recommended dose, cardiac safety, and antitumor activity of nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and the anti-HER-2 monoclonal antibody trastuzumab in patients with HER-2-overexpressing locally advanced nonoperable breast cancer (LABC) and metastatic breast cancer (MBC). Experimental Design: Women with measurable, previously untreated, HER-2-overexpressing LABC and MBC with a baseline left ventricular ejection fraction (LVEF) &amp;gt;50% received weekly trastuzumab in combination with escalating doses of weekly paclitaxel and TLC-D99 every 3 weeks for 6 cycles. LVEF monitoring was done every 3 weeks for the first 18 weeks and every 8 w…

AdultCancer Researchmedicine.medical_specialtyHeart DiseasesPaclitaxelUrologyBreast NeoplasmsAntibodies Monoclonal HumanizedAsymptomaticDisease-Free Survivalchemistry.chemical_compoundBreast cancerTrastuzumabAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansDoxorubicinNeoplasm Metastasisskin and connective tissue diseasesAgedEjection fractionbusiness.industryAntibodies MonoclonalGenes erbB-2Middle AgedTrastuzumabmedicine.diseaseMetastatic breast cancerUp-RegulationSurgeryOncologyPaclitaxelchemistryDoxorubicinHeart failureFemalemedicine.symptombusinessmedicine.drug
researchProduct